A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and...

Area of Science:

• Pharmaceutical Sciences
• Analytical Chemistry
• Regulatory Science

Background:

• The 2007 AAPS/FDA Bioanalytical Workshop report introduced new validation recommendations.
• The workshop aimed to harmonize validation principles for small and large molecules and revisit acceptance criteria.

Purpose of the Study:

• To evaluate the 3rd AAPS/FDA Bioanalytical Workshop recommendations using a risk-based approach.
• To compare the performance of five different decision rules for bioanalytical method validation.

Main Methods:

• Simulations were used to compare five decision rules: FDA, Total Error, beta-Expectation Tolerance, beta-gamma-Content Tolerance Interval, and the 4-6-20 rule.
• The rules were assessed based on their ability to control risk and ensure the acceptance of valid procedures.

Main Results:

• The beta-Expectation Tolerance Rule demonstrated appropriate risk control.
• The beta-gamma-Content Tolerance Interval was overly conservative, leading to unnecessary rejections.
• The FDA and AAPS/FDA Total Error Rules failed to meet objectives, posing a high risk of accepting unreliable results.

Conclusions:

• The beta-Expectation Tolerance Rule is recommended for controlling risk in bioanalytical method validation.
• Misinterpretations of procedure quality versus fitness for purpose and initial versus future performance impact rule effectiveness.
• Clearer decision rules are needed to ensure the reliability of bioanalytical data in studies.